Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenergic beta-Antagonists | 2 | 2024 | 43 | 0.950 |
Why?
|
| Heart Failure | 3 | 2024 | 396 | 0.940 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2024 | 53 | 0.860 |
Why?
|
| Pharmacists | 1 | 2023 | 50 | 0.860 |
Why?
|
| Text Messaging | 1 | 2023 | 29 | 0.850 |
Why?
|
| Patient Discharge | 2 | 2024 | 154 | 0.840 |
Why?
|
| Guideline Adherence | 1 | 2024 | 157 | 0.830 |
Why?
|
| Veterans | 4 | 2024 | 143 | 0.780 |
Why?
|
| Atrial Fibrillation | 2 | 2023 | 170 | 0.380 |
Why?
|
| Aged | 8 | 2024 | 6150 | 0.370 |
Why?
|
| Stroke | 2 | 2023 | 315 | 0.350 |
Why?
|
| Anticoagulants | 3 | 2024 | 127 | 0.310 |
Why?
|
| United States | 7 | 2024 | 4003 | 0.310 |
Why?
|
| Humans | 12 | 2024 | 17762 | 0.290 |
Why?
|
| Middle Aged | 5 | 2024 | 7988 | 0.270 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2024 | 128 | 0.260 |
Why?
|
| Inpatients | 2 | 2023 | 81 | 0.260 |
Why?
|
| Male | 9 | 2024 | 10106 | 0.260 |
Why?
|
| Qualitative Research | 2 | 2024 | 256 | 0.250 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2024 | 331 | 0.240 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 1923 | 0.230 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2024 | 10 | 0.230 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 18 | 0.230 |
Why?
|
| Hospitals, Veterans | 1 | 2024 | 34 | 0.230 |
Why?
|
| Noninvasive Ventilation | 1 | 2024 | 11 | 0.230 |
Why?
|
| Patient Preference | 1 | 2024 | 48 | 0.220 |
Why?
|
| Analgesics, Opioid | 2 | 2024 | 246 | 0.220 |
Why?
|
| Software | 1 | 2023 | 22 | 0.220 |
Why?
|
| Interviews as Topic | 1 | 2024 | 305 | 0.220 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2024 | 86 | 0.210 |
Why?
|
| Female | 8 | 2024 | 12740 | 0.210 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 161 | 0.210 |
Why?
|
| Colorado | 1 | 2023 | 164 | 0.210 |
Why?
|
| Caregivers | 1 | 2024 | 129 | 0.210 |
Why?
|
| Acute Coronary Syndrome | 1 | 2023 | 18 | 0.210 |
Why?
|
| Blood Pressure | 1 | 2024 | 302 | 0.210 |
Why?
|
| Reminder Systems | 1 | 2023 | 80 | 0.210 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 134 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 321 | 0.200 |
Why?
|
| Quality Improvement | 1 | 2023 | 194 | 0.190 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 238 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 382 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2023 | 172 | 0.190 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 179 | 0.180 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 292 | 0.180 |
Why?
|
| Hypertension | 1 | 2024 | 504 | 0.170 |
Why?
|
| Retrospective Studies | 4 | 2024 | 2461 | 0.130 |
Why?
|
| Adult | 3 | 2024 | 7678 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2023 | 2586 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2024 | 114 | 0.060 |
Why?
|
| Michigan | 1 | 2024 | 26 | 0.060 |
Why?
|
| Comprehension | 1 | 2024 | 17 | 0.060 |
Why?
|
| Analgesia | 1 | 2024 | 4 | 0.060 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 17 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2024 | 29 | 0.060 |
Why?
|
| Rivaroxaban | 1 | 2023 | 8 | 0.060 |
Why?
|
| Off-Label Use | 1 | 2023 | 14 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2024 | 100 | 0.060 |
Why?
|
| Health Literacy | 1 | 2024 | 39 | 0.060 |
Why?
|
| Ezetimibe | 1 | 2023 | 4 | 0.060 |
Why?
|
| Morphine Derivatives | 1 | 2023 | 4 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2023 | 85 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2023 | 46 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2023 | 17 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 151 | 0.050 |
Why?
|
| Aftercare | 1 | 2023 | 49 | 0.050 |
Why?
|
| Focus Groups | 1 | 2023 | 147 | 0.050 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 119 | 0.050 |
Why?
|
| Warfarin | 1 | 2023 | 74 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 188 | 0.050 |
Why?
|
| Communication | 1 | 2024 | 194 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2024 | 164 | 0.050 |
Why?
|
| Registries | 1 | 2024 | 472 | 0.050 |
Why?
|
| Prognosis | 1 | 2024 | 609 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 1330 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2023 | 1260 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 808 | 0.040 |
Why?
|
| Risk Factors | 1 | 2023 | 3356 | 0.030 |
Why?
|
Concepts
(78)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(2)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->